Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam

ClinicalTrials.gov ID: NCT01484977

Public ClinicalTrials.gov record NCT01484977. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The main purpose of this study is to evaluate the effectiveness of the study drug lacosamide (200-600 mg/day) when added to a stable dose of levetiracetam (1000-3000 mg/day) with withdrawal of the concomitant sodium channel blocking-antiepileptic drug (AEDs) in subjects not well controlled on their current regimen.

Study identification

NCT ID
NCT01484977
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
UCB Pharma
Industry
Enrollment
120 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 2011 (Type not available)
Primary completion
Dec 2013 (Actual)
Completion
Dec 2013 (Actual)
Last update posted
Jul 18, 2018

2011 – 2013

United States locations

U.S. sites
30
U.S. states
17
U.S. cities
30
Facility City State ZIP Site status
110 Huntsville Alabama — —
004 Phoenix Arizona — —
001 Fresno California — —
008 Orange California — —
030 Oxnard California — —
108 Sacramento California — —
025 Bradenton Florida — —
015 Ocala Florida — —
049 Panama City Florida — —
114 Port Charlotte Florida — —
012 Sarasota Florida — —
014 Tampa Florida — —
003 Wellington Florida — —
123 Louisville Kentucky — —
006 Hammond Louisiana — —
112 Waldorf Maryland — —
129 Golden Valley Minnesota — —
023 Springfield Missouri — —
088 Missoula Montana — —
020 Camden New Jersey — —
131 Greensboro North Carolina — —
002 Akron Ohio — —
027 Canton Ohio — —
022 Columbus Ohio — —
005 Dayton Ohio — —
013 Oklahoma City Oklahoma — —
028 Lubbock Texas — —
017 Salt Lake City Utah — —
139 Madison Wisconsin — —
024 Milwaukee Wisconsin — —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 24 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01484977, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 18, 2018 · Synced Oct 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01484977 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →